Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.

MLA

Owens, Gemma L., et al. “Ex Vivo Expanded Tumour-Infiltrating Lymphocytes from Ovarian Cancer Patients Release Anti-Tumour Cytokines in Response to Autologous Primary Ovarian Cancer Cells.” Cancer Immunology, Immunotherapy, vol. 67, no. 10, Oct. 2018, pp. 1519–31. EBSCOhost, https://doi.org/10.1007/s00262-018-2211-3.

APA

Owens, G. L., Price, M. J., Cheadle, E. J., Hawkins, R. E., Gilham, D. E., & Edmondson, R. J. (2018). Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. Cancer Immunology, Immunotherapy, 67(10), 1519–1531. https://doi.org/10.1007/s00262-018-2211-3

Chicago

Owens, Gemma L., Marcus J. Price, Eleanor J. Cheadle, Robert E. Hawkins, David E. Gilham, and Richard J. Edmondson. 2018. “Ex Vivo Expanded Tumour-Infiltrating Lymphocytes from Ovarian Cancer Patients Release Anti-Tumour Cytokines in Response to Autologous Primary Ovarian Cancer Cells.” Cancer Immunology, Immunotherapy 67 (10): 1519–31. doi:10.1007/s00262-018-2211-3.